ASCO 2019: highlights in HER2-positive metastatic breast cancer

In this study a clinically meaningful prolongation of PFS by 2.2 months was observed. In addition, the time to intervention for brain metastases was prolonged in the neratinib group and the cumulative incidence of brain metastases was lower as well. On the downside a high rate of grade 2 and  3 diarrhoea was observed.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSIONS: T3b, distinguished from minimal ETE, may be related to larger tumor size, higher prevalence of multifocality, LNM, DM, recurrence and worse RFS than no ETE, but it may not affect OS and may not independently predict recurrence in PTC patients. PMID: 31830859 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
CONCLUSIONS: The clinical content and evidence explanations in the adult thyroid nodule and differentiated thyroid cancer CPG are widely accepted and applied among ATA survey respondents. Future ATA CPG updates need to be optimized to best meet users' preferences regarding format, frequency and length. PMID: 31830853 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Publication date: Available online 14 December 2019Source: Social Science &MedicineAuthor(s): Catherine Bourgain, Lionel Pourtau, Chafika Mazouni, Martine Bungener, et Julia Bonastre
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
In this study, we investigate, in vitro, whether miRNA-593-5p inhibits NSCLC cell proliferation. To clarify its specific mechanism of inhibition, we used bioinformatics to predict its target genes and identified PLK1. Luciferase reporter assay confirmed the binding of miR-593-5p to the PLK1 3’-UTR in a sequence-specific manner in NSCLC cells. Additionally, we also found through Western blot and quantitative RT-PCR that miR-593-5p down-regulates the expression of PLK1 protein. Finally, PLK1 overexpression was shown to disinhibit NSCLC cell proliferation. Taken together, this evidence suggests that miR-593-5p inhibits ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
ConclusionUreteral neuroendocrine tumors are extremely rare. Neuroendocrine markers (CD56, CgA, Syn) and epithelial markers (CKpan, CK7) are usually helpful. Grimelius special staining and electron microscopy observation can help to make a final diagnosis. Radical surgery together with postoperative adjuvant chemotherapy can improve the survival of patients. Vimentin may play a role in predicting the prognosis.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Authors: Edelsberg J, Weycker D, Bensink M, Bowers C, Lyman GH Abstract Filgrastim prophylaxis, both primary and secondary, was rapidly incorporated into clinical practice in the 1990s. When pegfilgrastim became available in 2002, it quickly replaced filgrastim as the colony-stimulating factor (CSF) of choice for prophylaxis. Use of prophylaxis increased markedly in the first decade of this century and has stabilized during the present decade.Data concerning real-world CSF prophylactic practice patterns are limited but suggest that both primary and secondary prophylaxis are common, and that use is frequently inappr...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
ConclusionTTM is an alternative treatment modality for patients with cancer and is supported by a national policy in Thailand. To increase accountability to patients and other practitioners, TTM treatments should be refined to rely on scientific principles and practitioners of TTM should receive academic training. Practical treatment guidelines need to be established and thoroughly disseminated to TTM practitioners.Please cite this article as: Nootim P, Kapol N, Bunchuailua W, Poompruek P, Tungsukruthai P. Current state of cancer patient care incorporating Thai traditional medicine in Thailand: A qualitative study. J Integ...
Source: Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
By BISHAL GYAWALI MD Me-too deja vu I read the report of a phase 3 RCT of a “new” breast cancer drug but I had the feeling that I had already read this before. Later I realized that this was indeed a new trial of a new drug, but that I had read a very similar report of a very similar drug with very similar results and conclusions. This new drug is a PARP inhibitor called talazoparib and the deja vu was related to another PARP inhibitor drug called olaparib tested in the same patient population of advanced breast cancer patients with a BRCA mutation. The control arms were the same: physician ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Drug Discovery Pharmaceuticals Bishal Gyawali Cancer immunotherapy Oncology Source Type: blogs
ConclusionBuparlisib plus trastuzumab, as a chemotherapy-free regimen, demonstrated an acceptable safety profile but limited efficacy in patients with heavily pretreated, trastuzumab-resistant HER2-positive breast cancer, and in patients with progressive brain metastases also receiving capecitabine.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Diarrhoea | Docetaxel | HER2 | Herceptin | Neurology | Statistics | Study | Taxotere